TheEdgeResearch
Home / Stocks / RVTY

Revvity, Inc. (RVTY)

NYSE Healthcare Medical - Diagnostics & Research
$115.02 ▼ -0.61%
Market Cap
$12.83B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
1.07
52-Wk Range
81.22-118.3
CEO
Prahlad R. Singh
Country
US
Currency
USD

Revvity, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $115.02, down 0.61% on the session, giving a market capitalisation of $12.83B. On trailing twelve-month figures it carries a trailing P/E of 54.77, a net margin of 8.2%. Its beta of 1.07 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
54.77
Price / Sales
4.41
Price / Book
1.78
EV / EBITDA
19.75
Gross margin
52.1%
Operating margin
12.3%
Net margin
8.2%
Return on equity
Debt / equity
0.46
Current ratio
1.80
Dividend yield
0.2%
Payout ratio
13.4%
Company profile
Exchange
New York Stock Exchange
Employees
11,000
IPO date
1965-07-06
Headquarters
Waltham, MA, US
About Revvity, Inc.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Comparable companies

Revvity, Inc. is most often compared with the following Healthcare names:

ALGNCRLENSGEXASGHHIMSICLRQGENRDYSOLV
More research on RVTY
RVTY technical analysis RVTY TheEdge Score Compare against peers
Open full interactive analysis & DCF →